OMICS Group Conferences
Accelerating Scientific Discovery

3rd World Congress on Virology

November 20-22, 2013 DoubleTree by Hilton Baltimore-BWI Airport, USA

HIV vaccine development: An industrial perspective

Sanjay Phogat

Sanofi Pasteur, USA

Abstract

Even after two decade of HIV vaccine R&D, challenges posed by HIV vaccine development require us to rethink the traditional R&D industry vaccine development model and necessitate the establishment of broad-based public-private partnerships. The complexities of an HIV vaccine present many unknowns, both with respect to scientific, pre-clinical, clinical development and industrialization.

Sanofi Pasteur has been working on the development of an effective HIV vaccine for over two decades. It is now clear that the roadmap to developing an effective HIV vaccine is best managed by broad-based partnerships, not individual entities. A unique collaboration has emerged following the successful RV144 results, with the objective of pursuing research and development of the pox-prime/protein-boost HIV vaccine regimen.

The Pox-Protein Public-Private Partnership (P5) is an informal partnership between the U.S. National Institute for Allergies and Infectious Diseases (NIAID of the U.S. National Institute of health), The Bill & Melinda Gates Foundation (BMGF), the HIV Vaccine Trials Network (HVTN), the U.S. Military HIV Research Program (MHRP), Sanofi Pasteur, and Novartis vaccines. This collaboration is expected to further the field of HIV vaccine development by sharing resources and joining the forces of vaccine manufacturing, funding agencies, research organizations, governments, and experts in the field of HIV vaccine development.

HIV vaccine development is a global responsibility. To ensure an effective HIV vaccine will be delivered as quickly as possible, industry, academia, public sector, NGO and donors must work simultaneously in partnerships

The presentation will highlight two topics. An industrial perspective on HIV vaccine development and how the experience from developing pox vectors can guide basic "technological" research.